Cyclophosphamide Dosing in Lupus Nephritis

Secondary GNmedium

A 32-year-old woman with biopsy-proven active Class IV lupus nephritis (eGFR 70 mL/min/1.73 m2, urine protein-creatinine ratio 3.2 g/g) is to receive intravenous cyclophosphamide as part of initial therapy. When choosing between a high-dose (NIH) and a low-dose (Euro-Lupus) intravenous cyclophosphamide regimen, which statement best reflects the KDIGO 2024 recommendation?

  1. A.High-dose monthly (NIH) cyclophosphamide is preferred because it is more effective for all patients
  2. B.Low-dose (Euro-Lupus) cyclophosphamide is preferred for comparable efficacy with less toxicityCorrect
  3. C.Daily oral cyclophosphamide for 12 months is the standard induction regimen today
  4. D.Cyclophosphamide is used only after mycophenolate mofetil has clearly failed

Explanation

For active Class III/IV lupus nephritis, KDIGO 2024 endorses low-dose intravenous cyclophosphamide (Euro-Lupus regimen: 500 mg every 2 weeks for 6 doses) as a preferred cyclophosphamide option because it delivers efficacy comparable to the high-dose NIH regimen (0.5-1 g/m2 monthly) while producing substantially less gonadal toxicity, infection, and cumulative exposure. High-dose cyclophosphamide is not universally superior, oral daily dosing is not the standard IV induction approach, and cyclophosphamide is a first-line induction option (alongside mycophenolic acid analogs), not merely salvage therapy.

Why each option

A.
The Euro-Lupus trial showed low-dose IV cyclophosphamide is as effective as high-dose NIH dosing, so high-dose is not universally preferred.
B.
Correct: low-dose (Euro-Lupus) IV cyclophosphamide gives comparable efficacy with less toxicity and is a preferred cyclophosphamide regimen.
C.
Prolonged daily oral cyclophosphamide is not the standard induction regimen and adds cumulative toxicity.
D.
Cyclophosphamide is a recognized first-line induction agent, not reserved for mycophenolate failure.

Reference: KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis, Kidney Int 2024;105(1S):S1-S69; Houssiau FA et al. Euro-Lupus Nephritis Trial. Arthritis Rheum 2002;46:2121-2131.

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More Secondary GN questions

Browse other topics